as of —
₹—
Change
—
Day Open
₹—
Day High
₹—
Day Low
₹—
NSE Close — 19 Nov 2026
₹24.97
Change
-0.48 (-1.89%)
Open
₹25.33
Prev. Close
₹25.45
Day High
₹25.77
Day Low
₹24.8
Volume Analysis
Traded
2,077,848
Delivered
1,128,517
Delivery %
54.31%
End-of-day NSE price via the official Bhavcopy — updated once daily after market close, not a live tick.
Strengths, Weaknesses, Opportunities & Threats
Strengths (1)
- •Strong operating margin (24.0%)
Weaknesses (0)
No signal for this stock
Opportunities (3)
- •Strong 3-year EPS growth (53.3%)
- •Strong 3-year revenue growth (15.0%)
- •FII holding has been rising
Threats (0)
No signal for this stock
Rule-based signals from the fundamentals below — not investment advice.
Pivot Levels
| Type | R3 | R2 | R1 | Pivot | S1 | S2 | S3 |
|---|---|---|---|---|---|---|---|
| Classic | ₹26.53 | ₹26.15 | ₹25.56 | ₹25.18 | ₹24.59 | ₹24.21 | ₹23.62 |
| Fibonacci | ₹26.15 | ₹25.78 | ₹25.55 | ₹25.18 | ₹24.81 | ₹24.58 | ₹24.21 |
| Camarilla | ₹25.24 | ₹25.15 | ₹25.06 | ₹25.18 | ₹24.88 | ₹24.79 | ₹24.7 |
Support/resistance levels for today, calculated from the previous trading day's high/low/close.
Absolute Returns
YTD
-83.16%
1 Week
-6.58%
1 Month
-2.58%
3 Months
+74.86%
6 Months
+79.51%
1 Year
-84.03%
2Y/3Y/5Y not shown yet — price history tracking only goes back to mid-2025 so far.
Stock Vitals
Computed from the latest available annual financials.
Graham Number
₹5.11
Current price is above the Graham Number — Benjamin Graham's estimate of fair value based on earnings and book value.
DuPont ROE Breakdown
47.58%
Net margin 15.0% × asset turnover 0.52x × equity multiplier 6.1x
Company Overview
Sector
Healthcare
Market Cap
₹1,348 Cr
P/E (TTM)
37.8
ROE
18.4%
Book Value
₹4.84
Face Value
₹2.0
Source: Screener.in (Consolidated figures) — data as of 18 Nov 2026. Not investment advice.
TopFund Analysis
Anlon Healthcare Limited lands in the middle of the pack on TopFund's composite fundamentals check within the Healthcare sector, at 54/100. The strongest factor is Financial Strength (100/100), while Cash Flow (0/100) is the weakest area to weigh before deciding. Notably: Strong operating margin (24.0%). Strong 3-year EPS growth (53.3%).
TopFund Score — Fundamentals Quality
54/100 — AverageData confidence: 78/100 (Moderate Confidence) — based on how complete and how fresh the underlying data is.
As of 19 Nov 2026 · How we calculate this →
Financial Strength
Growth
Valuation
Cash Flow
Corporate Governance
Momentum
Institutional Ownership
Business Quality
Risk & Volatility
Liquidity
From Screener.in
- −Though the company is reporting repeated profits, it is not paying out dividend
- −Company might be capitalizing the interest cost
- −Company has high debtors of 220 days.
Not investment advice — an automated read of public fundamentals data, for research context only.
Corporate Actions
We have attached herewith earning call transcript for the H1/Q2 FY-27. Kindly take the same on your record. Thank you.
Q2 FY27 earnings call audio recording uploaded on November 3, 2026.
We have attached herewith copy of newspaper publication. Kindly take the same on your record. Thank you.
We have attached herewith Investor Presentation as per Regulation 30 of SEBI (LODR) Regulation, 2015. Kindly take the same on your record. Thank you.
Board approved Q2 and H1 FY2026 standalone and consolidated results on October 29, 2026.
Source: BSE regulatory filings, via Screener.in.
Quarterly Results
Last several quarters
| Jun 2024 (S) | Sep 2024 (S) | Dec 2024 (S) | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales + | 38 | 24 | 9 | 49 | 33 | 52 | 36 | 51 | 88 | 106 |
| Expenses + | 31 | 17 | 9 | 32 | 27 | 38 | 23 | 36 | 72 | 80 |
| Operating Profit | 7 | 8 | 1 | 17 | 6 | 14 | 12 | 15 | 16 | 25 |
| OPM % | 18.0% | 31.0% | 6.0% | 35.0% | 19.0% | 26.0% | 35.0% | 30.0% | 18.0% | 24.0% |
| Other Income + | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Interest | 1 | 1 | 1 | 1 | 1 | 1 | 2 | 1 | 1 | 1 |
| Depreciation | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 1 | 1 |
| Profit before tax | 5 | 6 | 0 | 15 | 5 | 12 | 11 | 14 | 14 | 23 |
| Tax % | 17.0% | 58.0% | 759.0% | -7.0% | 29.0% | 25.0% | 51.0% | 23.0% | 39.0% | 27.0% |
| Net Profit + | 5 | 3 | -2 | 17 | 4 | 9 | 5 | 11 | 8 | 17 |
| EPS in Rs | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Raw PDF | — | — | — | — | — | — | — | — | — | — |
| YoY Sales growth | — | — | — | — | — | — | — | 4 | 163 | 102 |
Source: Screener.in — figures in ₹ Crores unless marked %.
Profit & Loss (Yearly)
| Mar 2021 (S) | Mar 2022 (S) | Mar 2023 (S) | Mar 2024 (S) | Mar 2025 | Mar 2026 | TTM | |
|---|---|---|---|---|---|---|---|
| Sales + | 16 | 57 | 113 | 66 | 120 | 172 | 280 |
| Expenses + | 21 | 52 | 100 | 51 | 88 | 124 | 211 |
| Operating Profit | -5 | 6 | 13 | 16 | 32 | 48 | 68 |
| OPM % | -32.0% | 10.0% | 11.0% | 24.0% | 27.0% | 28.0% | 24.0% |
| Other Income + | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Interest | 3 | 4 | 4 | 4 | 4 | 4 | 4 |
| Depreciation | 2 | 2 | 2 | 2 | 2 | 2 | 3 |
| Profit before tax | -10 | 0 | 7 | 10 | 27 | 43 | 62 |
| Tax % | 3.0% | 0.0% | 17.0% | 1.0% | 24.0% | 32.0% | — |
| Net Profit + | -10 | 0 | 6 | 10 | 21 | 29 | 42 |
| EPS in Rs | 0 | 0 | 0 | 0 | 1 | 1 | 1 |
| Dividend Payout % | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — |
| Sales growth | — | 258 | 97 | -41 | — | 43 | — |
Source: Screener.in — figures in ₹ Crores unless marked %.
Balance Sheet
| Mar 2021 (S) | Mar 2022 (S) | Mar 2023 (S) | Mar 2024 (S) | Mar 2025 | Mar 2026 | Sep 2026 | |
|---|---|---|---|---|---|---|---|
| Reserves | -10 | -10 | -5 | 5 | 41 | 177 | 151 |
| Borrowings + | 54 | 62 | 70 | 81 | 67 | 44 | 72 |
| Other Liabilities + | 16 | 21 | 34 | 26 | 34 | 100 | 123 |
| Total Liabilities | 71 | 85 | 112 | 128 | 181 | 374 | 453 |
| Fixed Assets + | 29 | 27 | 26 | 27 | 23 | 58 | 79 |
| CWIP | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
| Investments | 0 | 2 | 4 | 1 | 1 | 1 | 1 |
| Other Assets + | 43 | 56 | 82 | 100 | 158 | 315 | 371 |
| Total Assets | 71 | 85 | 112 | 128 | 181 | 374 | 453 |
| Equity Capital | 12 | 12 | 12 | 16 | 40 | 53 | 106 |
Source: Screener.in — figures in ₹ Crores unless marked %.
Cash Flow
| Mar 2021 (S) | Mar 2022 (S) | Mar 2023 (S) | Mar 2024 (S) | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|
| Cash from Operating Activity + | -15 | -2 | -3 | -3 | -22 | -59 |
| Cash from Investing Activity + | -2 | 0 | 0 | -3 | 2 | -36 |
| Cash from Financing Activity + | 16 | 3 | 2 | 8 | 19 | 118 |
| Net Cash Flow | -2 | 1 | -1 | 2 | -1 | 23 |
| Free Cash Flow | -15 | -2 | -3 | -7 | -19 | -95 |
| CFO/EBITDA Share of operating profit converting into cash: CFO (before tax) / Operating Profit | 291 | -32 | -23 | -21 | -85 | -114 |
Source: Screener.in — figures in ₹ Crores unless marked %.
Shareholding Pattern
Quarter-by-quarter — Promoters, FII, DII & public holding trend
| Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 | |
|---|---|---|---|---|---|
| Public | 44.49% | 42.6% | 42.4% | 44.43% | 46.02% |
| Promoters | 52.68% | 52.68% | 52.68% | 52.68% | 52.68% |
| FII | 0.0% | 0.23% | 0.32% | 1.67% | 0.99% |
| DII | 2.83% | 4.49% | 4.6% | 1.23% | 0.3% |
Source: Screener.in — quarterly shareholding disclosures.
Peers Comparison
Healthcare — ranked by market cap
| Company | Market Cap (Cr) | P/E | P/B | ROE |
|---|---|---|---|---|
| Anlon Healthcare Limited (this stock) | 1,348 | 37.8 | 5.25 | 18.4% |
| Fermenta Biotech Ltd. | 1,367 | 29.4 | 3.27 | 17.3% |
| Shalby Limited | 1,317 | 33.6 | 1.29 | 2.45% |
| Jagsonpal Pharmaceuticals | 1,402 | — | 5.82 | — |
| Kopran Ltd | 1,281 | 32.6 | 2.44 | 4.91% |
| Gujarat Kidney N Sup Sp L | 1,269 | 66.8 | 4.82 | 11.1% |
| Amrutajan Health Ltd | 1,461 | 71.7 | 13.58 | 20.0% |
Which Mutual Funds Hold Anlon Healthcare Limited?
Frequently Asked Questions about Anlon Healthcare Limited
Anlon Healthcare Limited (AHCL) closed at ₹24.97 on NSE on 19 November 2026, down 0.48 (1.89%) from the previous close.
Anlon Healthcare Limited trades on the NSE (National Stock Exchange of India) under the symbol AHCL.
Anlon Healthcare Limited has a trailing twelve-month P/E (price-to-earnings) ratio of 37.8.
Anlon Healthcare Limited has a dividend yield of 0.0%.
Anlon Healthcare Limited's 52-week high is ₹37.6 and its 52-week low is ₹10.3.
Anlon Healthcare Limited has a market capitalisation of ₹1,348 crore.
Anlon Healthcare Limited has a TopFund Quality Score of 54/100 (Average), a composite of profitability, balance-sheet health, growth and valuation. This is an analytical score based on public data, not personalized investment advice — see the full breakdown below before deciding.
Community Sentiment
What are other investors saying about Anlon Healthcare Limited?
No votes yet — be the first to share your view.
Sign in to voteDiscussion
User-generated content — not investment advice, and not verified or endorsed by TopFund.
Sign in to join the discussionNo comments yet — start the discussion.